Laronde is building a company fueled by their modular Endless RNA™ (eRNA) platform, which will be supported by a large-scale digital and manufacturing infrastructure with the bold vision of 100 new medicines within the next decade. With eRNA, Laronde is making new therapeutics that will become essential medicines of the future.

In October 2023, Flagship Pioneering announced the merger of Laronde and Senda Biosciences, forming Sail Biomedicines, a new company focused on designing and deploying fully programmable medicines.